ECO ANIMAL HEALTH GROUP PLC

Regulatory Filings • Nov 10, 2025

National Storage Mechanism | Additional information

RNS Number : 7800G

Eco Animal Health Group PLC

10 November 2025

10 November 2025

ECO Animal Health Group plc

("ECO" or the "Company")

EMA Positive Opinion Received for ECOVAXXIN® MS poultry vaccine

Key milestone establishes roadmap for H2 2026 EU commercial launch

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a Positive Opinion recommending the granting of EU marketing authorisation for ECOVAXXIN® MS, a poultry vaccine against Mycoplasma synoviae.

Based on the CVMP's Positive Opinion, the EMA is expected to issue a marketing authorisation during the first quarter of 2026, and ECO Animal Health anticipates making ECOVAXXIN® MS commercially available in the European Union in the second half of 2026.

ECOVAXXIN® MS provides active immunisation of future layer and breeder chickens from four weeks of age, helping to reduce air-sac and foot-pad lesions caused by Mycoplasma synoviae infections. Air-sac and foot-pad lesions cause economic loss, especially in laying hens, and the number of eggs produced by affected layers can be reduced by 5-10%.

ECO Animal Health expects to submit additional geographic marketing authorisation requests for ECOVAXXIN® MS, as well as submissions for further vaccine products in its R&D pipeline, during the next 12 months.

David Hallas, Chief Executive Officer of ECO Animal Health, said: "We are delighted to have received a Positive Opinion from the CVMP for ECOVAXXIN MS. This significant milestone paves the way for a  mid-2026 EU launch for this innovative vaccine product, in-line with our prior guidance.

"This marks an exciting time for the Company, with further submissions expected over the next 12 months for additional products from our R&D pipeline, underpinning ECO's next phase of growth. I'd like to thank our R&D, regulatory, marketing, and technical teams for their hard work in getting us to this point and look forward to updating the market on our continued progress."

-Ends-

Contacts

ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)	020 8447 8899
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson	020 3709 5700
Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies Sam Butcher	020 7496 3000
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden	020 3100 2000
Equity Development Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

Click here for more information: https://ecoanimalhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDZMGMNLDGKZM